)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
MDxHealth
MDxHealth (MDXH) investor relations material
MDxHealth Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
Q3 results fell short of expectations after accelerated sales-team turnover disrupted commercial execution following the Resolve discontinuation.
A commercial reorganization split sales and marketing under direct CEO oversight; management expects the team to be fully staffed and trained by Q4-end or entering Q1 2027, with growth returning in 2027.
Financial highlights
Q3 continuing-operations revenue was $22.711M versus $22.728M a year earlier; 9M revenue rose 9% to $73.817M from $67.685M.
Q3 operating expenses rose 16% to $22.2M and operating loss widened 86% to $8.128M from $4.4M.
Continuing-operations net loss rose 26% to $12.259M from $9.7M; adjusted EBITDA was $(6.281)M versus $(0.912)M.
For 9M, operating loss widened 102% to $21.391M, continuing-operations net loss rose 21% to $31.433M, and adjusted EBITDA was $(13.914)M versus $(0.914)M.
Outlook and guidance
No Q4 revenue guidance was provided; management expects Q4 revenue broadly in line with Q3, with recovery starting in Q1 2027 and accelerating through the year.
New sales representatives may need one to two quarters to ramp; management aims to regain prior 20% top-line growth but is unlikely to guide to that rate for 2027.
Management targets sustainable growth and adjusted EBITDA profitability; it said the prior expectation of positive adjusted EBITDA in Q4 is not as far off as it may seem.
Strategic AI initiatives are planned for H1 2027, including operational applications and a digital-pathology partnership intended to support GPS.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MDxHealth
- Prostate diagnostics portfolio targets growth as H1 2026 revenue rose 14% YoY.MDXH
Corporate presentation - Comprehensive prostate cancer diagnostics drive double-digit revenue growth and market expansion.MDXHCorporate presentation
- Q2 revenue up 16% year-over-year, record sequential growth, and positive EBITDA outlook reaffirmed.MDXHQ2 2026
- Comprehensive urology solutions and robust growth drive revenue guidance to $110–115M for 2026.MDXHCorporate presentation
- Exited Resolve UTI business, focusing on prostate cancer diagnostics and AI-driven growth.MDXHQ1 2026
- Strong revenue growth and clinical validation position for continued expansion in urology diagnostics.MDXHCorporate presentation
- Revenue up 20% in 2025; 2026 guidance targets $137-140M on expanded urology menu.MDXHCorporate presentation
- 2026 guidance targets 27–30% revenue growth and 10% EBITDA margin, driven by ExoDx integration.MDXHQ4 2025
- Precision diagnostics firm seeks up to $200M in shares amid ongoing losses and market risks.MDXHRegistration Filing
Next MDxHealth earnings date
Q4 202625 Feb, 2027
MDxHealth
Next MDxHealth earnings date
Q4 202625 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
MDxHealth SA is a molecular diagnostics company focused on the development and commercialization of genomic tests for cancer. Specializing in urologic oncology, the company provides non-invasive tests that assist in the diagnosis and management of prostate and bladder cancers. MDxHealth’s tests use epigenetic and genetic markers to deliver accurate, personalized insights that support healthcare providers in making informed treatment decisions. The company is headquartered in Herstal, Belgium, and its shares are listed on the Euronext Brussels and the Nasdaq.